Current therapies for ANCA-associated vasculitis Review uri icon


MeSH Major

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
  • Antirheumatic Agents
  • Glucocorticoids
  • Immunosuppressive Agents
  • Plasma Exchange


  • The ANCA-associated vasculitides, granulomatosis with polyangiitis (GPA, formerly Wegener's), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss), are a group of multisystem autoimmune diseases characterized by necrotizing small- to medium-vessel vasculitis and the presence of anti-neutrophil cytoplasmic antibodies. Current therapeutic strategies consist of glucocorticoids in conjunction with either conventional or biologic agents for both induction of remission and remission maintenance. Treatment goals include reducing toxicity of induction therapy, preventing disease relapse, and limiting overall accrual of both disease-related damage and treatment-related morbidity. Future research directions include investigation of the optimal duration and frequency of maintenance therapy as well as development of targeted therapeutic agents, which is enhanced by emerging insights into disease pathogenesis.

publication date

  • January 2015



  • Review



  • eng

Digital Object Identifier (DOI)

  • 10.1146/annurev-med-011514-023051

PubMed ID

  • 25341007

Additional Document Info

start page

  • 227

end page

  • 40


  • 66